Cerus (CERS) Expected to Release Earnings on Thursday

Cerus (NASDAQ:CERS) will likely be announcing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Cerus to post earnings of ($0.0133) per share and revenue of $62.90 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Cerus (NASDAQ:CERS) last issued its earnings results on Thursday, April 30th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. Cerus had a negative net margin of 4.41% and a negative return on equity of 15.18%. The company had revenue of $59.89 million during the quarter, compared to the consensus estimate of $55.68 million. On average, analysts expect Cerus to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Trading Down 3.2%

Shares of CERS stock opened at $3.02 on Thursday. Cerus has a 52-week low of $1.15 and a 52-week high of $3.47. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.06 and a current ratio of 1.63. The firm has a market capitalization of $605.12 million, a PE ratio of -60.40 and a beta of 1.77. The stock has a fifty day simple moving average of $2.83 and a two-hundred day simple moving average of $2.40.

Insider Transactions at Cerus

In related news, COO Vivek K. Jayaraman sold 42,359 shares of Cerus stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $2.94, for a total transaction of $124,535.46. Following the completion of the transaction, the chief operating officer directly owned 1,694,348 shares of the company’s stock, valued at approximately $4,981,383.12. The trade was a 2.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Eric Bjerkholt sold 20,454 shares of the company’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $2.60, for a total transaction of $53,180.40. Following the transaction, the director owned 261,679 shares in the company, valued at $680,365.40. The trade was a 7.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 256,071 shares of company stock worth $747,894 in the last quarter. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Cerus

Several institutional investors have recently added to or reduced their stakes in the company. Cibc World Markets Corp purchased a new position in shares of Cerus during the fourth quarter valued at approximately $25,000. CIBC Bancorp USA Inc. bought a new position in shares of Cerus during the third quarter valued at approximately $31,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cerus in the first quarter worth approximately $32,000. Aquatic Capital Management LLC purchased a new stake in shares of Cerus in the third quarter worth approximately $35,000. Finally, MML Investors Services LLC bought a new stake in shares of Cerus during the 4th quarter worth approximately $37,000. Institutional investors own 78.37% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research note on Friday, May 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Cerus in a research note on Thursday, June 18th. Zacks Research raised Cerus from a “strong sell” rating to a “hold” rating in a report on Thursday, April 30th. Finally, Wall Street Zen raised Cerus from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Cerus has a consensus rating of “Hold” and an average price target of $4.00.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.